|
KMID : 0941820220320030185
|
|
Korean Journal of Clinical Pharmacy
2022 Volume.32 No. 3 p.185 ~ p.190
|
|
|
Evaluation of Clinical Outcomes by Therapeutic Dosing Interval of Denosumab (Prolia®) and Calcium-Vitamin D Prescriptions
|
|
Kim You-Kyeong
Kim Jung-Hyun
Doh Hyun-Jeong
Jeong Young-Mi
Lee Jeong-Hwa
Lee Ju-Yeun
Lee Euni
|
|
|
Abstract
|
|
|
Background: Denosumab (Prolia®) is administered every 6 months for osteoporosis treatment. Co-administration of calcium andvitamin D is required to minimize hypocalcemia risk. We evaluated clinical outcomes based on the administration interval ofdenosumab and co-prescription with calcium-vitamin D combination products.
Methods: A retrospective study was conducted usingelectronic medical records from 668 patients who started denosumab therapy between January 1 and December 31, 2018, at SeoulNational University Bundang Hospital. Clinical outcomes, as measured by changes in T-score, were evaluated by the intervals andconcurrent prescriptions with calcium?vitamin D combination products.
Results: Of the 668 patients, 333 patients met the eligibilitycriteria. These patients were divided into two groups based on appropriateness of the administration interval: “Appropriate” (304patients, 91.3%) and “Inappropriate” (29 patients, 8.3%). T-score changes were significantly higher in the “Appropriate” than in the“Inappropriate” group (0.30±0.44 vs. 0.13±0.37, p=0.048). At the beginning of the treatment, 221 patients (66.4%) were prescribedcalcium-vitamin D combination products, but the changes in T-scores were not significantly different by the prescription status of theproduct (0.29±0.46 vs. 0.28±0.38, p=0.919).
Conclusion: T-scores were significantly improved in patients with appropriateadministration intervals. No significant changes in T-scores were observed by the prescription status with calcium-vitamin Dcombination products. For optimal treatment outcomes, prescribers should encourage adherence to the approved prescriptioninformation on dosage and administration, and pharmacists should provide medication counseling for patients.
|
|
|
KEYWORD
|
|
|
Osteoporosis, denosumab, drug utilization review
|
|
|
FullTexts / Linksout information
|
|
|
|
|
|
Listed journal information
|
|
|
|